Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)

Real-time Quote. Real-time Tradegate - 09/30 11:57:14 am
67.195 EUR   -1.23%
07:26aDJNovo Nordisk Announces Job Cuts
02:40a SANOFI : deal raises concerns about Boehringer
09/29 SANOFI : Understanding diabetes in the developing world
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Sanofi: Tests Show Zaltrap Improves Colorectal Cancer Survival Rate

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/08/2012 | 07:44am CEST

French drug company Sanofi SA (>> SANOFI) Monday said results from the pivotal Phase III Velour study evaluating Zaltrap showed improvement in overall survival rate to colorectal cancer.

MAIN FACTS:

- Sanofi said the Journal of Clinical Oncology published the results of the study evaluating Zaltrap effects.

- In the Velour trial evaluating metastatic colorectal cancer patients previously treated with an oxaliplatin-containing regimen, Zaltrap in combination with the Folfiri chemotherapy regimen (5-fluorouracil, leucovorin, irinotecan) showed a statistically significant improvement in overall survival, progression-free survival, and the overall tumor response rate versus placebo plus Folfiri.

- The Velour data supported the regulatory approval of Zaltrap by the U.S. Food and Drug Administration (FDA) on August 3, 2012 after a Priority Review.

- Zaltrap is under review at the European Medicines Agency and other regulatory agencies worldwide, Sanofi says.

-Write to Inti Landauro at inti.landauro@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SANOFI
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
07:26aDJNovo Nordisk Announces Job Cuts
02:40a SANOFI : deal raises concerns about Boehringer
09/29 SANOFI : Understanding diabetes in the developing world
09/27 SANOFI : BARDA Grants $ 43.2 million USD to Sanofi Pasteur for Zika?
09/27 FDA GRANTS PRIORITY REVIEW FOR DUPIL : REGN), Sanofi SA (NYSE:SNY)
09/27 SANOFI : (SNY) Receives $43.2M BARDA Grant for Zika Vaccine Development
09/27 SANOFI : AHN doctors, patients to have role in diabetic device development
09/26DJLufthansa Hits Limits of ECB Bond Buying
09/26 SANOFI : BARDA Grants $43.2 million USD to Sanofi Pasteur for Zika ​
09/26 SANOFI : BARDA Grants $43.2 million USD to Sanofi Pasteur for Zika
More news
Sector news : Pharmaceuticals - NEC
07:26aDJNovo Nordisk Announces Job Cuts
09/29DJGLAXOSMITHKLINE : Appoints New Consumer Healthcare Chief
09/29DJNOVO NORDISK A/S : to Cut 1,000 Jobs Amid Growing Competition -- Update
09/28DJINTRA CELLULAR THERAPIES : Shares Plunge After Disappointing Drug Trial Results
09/28DJGLAXOSMITHKLINE : to Sell Remaining 6.2% Stake in Aspen Pharmacare
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09/29 Yellen And Clinton Combo To Take Market Higher
09/27 Novo Shows Its Devotion To Tresiba's Cause
09/26 FDA accepts dupilumab BLA for review; action date March 29, 2017
09/26 MANNKIND : Afrezza Scripts Approach 300; Trajectory Is Still Low
09/26 Amgen's New Products Have Ample Insurance Coverage In The U.S.
Advertisement
Financials (€)
Sales 2016 36 859 M
EBIT 2016 9 283 M
Net income 2016 5 275 M
Debt 2016 5 441 M
Yield 2016 4,31%
P/E ratio 2016 15,60
P/E ratio 2017 14,30
EV / Sales 2016 2,53x
EV / Sales 2017 2,53x
Capitalization 87 694 M
More Financials
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 26
Average target price 82,5 €
Spread / Average Target 21%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
JÚr˘me Contamine Chief Financial Officer & EVP-Finance
Elias E. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-13.45%98 367
JOHNSON & JOHNSON14.16%320 836
ROCHE HOLDING LTD.-11.51%216 029
NOVARTIS AG-10.14%209 049
PFIZER INC.3.22%202 108
MERCK & CO., INC.17.21%171 194
More Results